PriceTargets.com logo

RadNet - RDNT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $74.75
  • Forecasted Upside: -9.02%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$82.16 As of 11/20/2024 01:00 AM ET
▲ +2.31 (2.89%)

This chart shows the closing price for RDNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RadNet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDNT

Analyst Price Target is $74.75
▼ -9.02% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for RadNet in the last 3 months. The average price target is $74.75, with a high forecast of $80.00 and a low forecast of $60.00. The average price target represents a -9.02% upside from the last price of $82.16.

This chart shows the closing price for RDNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in RadNet. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/4/2024SidotiUpgradeStrong-Buy
9/23/2024Truist FinancialBoost TargetBuy ➝ Buy$70.00 ➝ $80.00
9/19/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$75.00 ➝ $80.00
9/6/2024BarclaysUpgradeEqual Weight ➝ Overweight$57.00 ➝ $79.00
8/8/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$51.00 ➝ $57.00
7/15/2024Truist FinancialBoost TargetBuy ➝ Buy$63.00 ➝ $70.00
7/11/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$61.00 ➝ $75.00
7/10/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$48.00 ➝ $51.00
5/15/2024Truist FinancialReiterated RatingBuy ➝ Buy$55.00 ➝ $63.00
5/10/2024Raymond JamesBoost TargetOutperform ➝ Outperform$50.00 ➝ $60.00
3/28/2024Truist FinancialReiterated RatingBuy ➝ Buy$51.00 ➝ $55.00
3/22/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$47.00 ➝ $58.00
3/6/2024BarclaysInitiated CoverageEqual Weight$48.00
3/4/2024Truist FinancialBoost TargetBuy ➝ Buy$42.00 ➝ $51.00
12/8/2023Truist FinancialBoost TargetBuy ➝ Buy$40.00 ➝ $42.00
8/31/2023Truist FinancialInitiated CoverageBuy$40.00
3/31/2023CJS SecuritiesInitiated CoverageOutperform$30.00
3/3/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$30.00
8/12/2021Raymond JamesDowngradeOutperform ➝ Market Perform
8/12/2021BarclaysInitiated CoverageOverweight$39.00
6/14/2021SidotiBoost TargetBuy$30.00 ➝ $40.00
3/9/2021Raymond JamesBoost TargetOutperform$22.00 ➝ $26.00
8/11/2020Raymond JamesBoost TargetOutperform$18.50 ➝ $22.00
5/26/2020SidotiBoost TargetBuy$17.00 ➝ $23.00
2/21/2020SidotiBoost TargetBuy$23.00 ➝ $28.00
12/2/2019SidotiBoost TargetBuy$20.00 ➝ $23.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 10 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 18 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 11 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 10 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 14 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 13 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 13 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

RadNet logo
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $82.16
Low: $79.69
High: $82.19

50 Day Range

MA: $70.04
Low: $62.30
High: $86.38

52 Week Range

Now: $82.16
Low: $31.55
High: $93.65

Volume

558,761 shs

Average Volume

554,469 shs

Market Capitalization

$6.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of RadNet?

The following Wall Street sell-side analysts have issued research reports on RadNet in the last twelve months: Barclays PLC, Jefferies Financial Group Inc., Raymond James, Sidoti, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for RDNT.

What is the current price target for RadNet?

0 Wall Street analysts have set twelve-month price targets for RadNet in the last year. Their average twelve-month price target is $74.75, suggesting a possible downside of 9.0%. Truist Financial Co. has the highest price target set, predicting RDNT will reach $80.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $60.00 for RadNet in the next year.
View the latest price targets for RDNT.

What is the current consensus analyst rating for RadNet?

RadNet currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDNT will outperform the market and that investors should add to their positions of RadNet.
View the latest ratings for RDNT.

What other companies compete with RadNet?

Other companies that are similar to RadNet include Genetron, Renalytix, Natera, Laboratory Co. of America and Quest Diagnostics. Learn More about companies similar to RadNet.

How do I contact RadNet's investor relations team?

RadNet's physical mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company's listed phone number is (310) 445-2800 and its investor relations email address is [email protected]. The official website for RadNet is www.radnet.com. Learn More about contacing RadNet investor relations.